Christophe Quéva
@garovirus.bsky.social
Drug developer oncology immunology, biotech executive.
Congratulations for a very nice study. The generation of a selective brain permeant ADAR1 inhibitor is a high hurdle. Could a similar activation of anti viral response be achieved with Oncolytic Viruses?
September 4, 2025 at 5:35 AM
Congratulations for a very nice study. The generation of a selective brain permeant ADAR1 inhibitor is a high hurdle. Could a similar activation of anti viral response be achieved with Oncolytic Viruses?
